Intracranial pressure monitoring market Companies

Medtronic (US) Acquired Rafale Medical in October 2023, gaining access to Rafale's innovative NeuroGuard ICP monitoring system with its unique sensor design. This acquisition strengthens Medtronic's position in the market and potentially paves the way for further innovation in ICP monitoring technology.

Brainlab (Germany) Received FDA clearance for its iSAM ICP monitoring system in June 2023. This system offers real-time pressure insights directly integrated into Brainlab's surgical navigation platform, enhancing workflow efficiency and potentially improving surgical outcomes.

Raumedic (Germany) Announced the CE marking of its Raumed Home ICP device in December 2023, marking a significant step towards home-based ICP monitoring for patients with hydrocephalus. This development could increase accessibility and quality of life for patients.

Natus Medical Incorporated (US) Completed the acquisition of Micromed Holding SAS ("Micromed") in November 2022, strengthening their neurophysiology portfolio and potentially expanding their reach in the ICP monitoring market.

Brain4care (Brazil) Developed a non-invasive ICP monitoring method using high blood pressure measurements, approved by FAPESP in July 2023. This innovative approach could offer affordable and accessible ICP monitoring options, particularly in resource-limited settings.

• Medtronic (Ireland)

• Codman & Shurtleff Inc. (U.S.)

• RAUMEDIC AG (Germany)

• Spiegelberg GmbH & Co. KG (Germany)

• Natus Medical Incorporated (U.S.)

• Gaeltec Devices (U.K.)

• Third Eye Diagnostics (U.S.)

• Vivonics Inc. (U.S.)

• DePuy Synthes (U.S.)